ClinicalTrials.gg
Not yet recruitingNCT07859150Updated Oct 5, 2026

Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)

A Phase 4 interventional study of Semaglutide weekly injection and Placabo in Morbid Obesity, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.

Planned enrollment
24th of 69
104 · median 90
Started
2026
with 9 others
Phase 4
6 of 76
5 open now
Primary completion
2029-04
later than 14 of 15 live
Registered
69th of 76
by date
Lead sponsor
8 of 76
General Committee of Teaching Hospitals and Institutes, Egypt

Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is the 24th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 14 of the 15 other live ones, and was the 69th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Obesity, Morbid with a site in Egypt, or all of them as a file.
02

Study summary

Metabolic and bariatric surgery (MBS) is the most effective durable treatment for severe obesity, yet a clinically meaningful proportion of patients experience recurrent weight gain after an initially successful operation. Until recently, research and care in this area were limited by the absence of standardized definitions: reported prevalence of weight recurrence ranged from under 10% to over 90% depending on the metric and threshold applied, and treatment decisions varied by provider.

In 2026, an international two-round modified Delphi study of 66 experts across surgery, obesity medicine, gastroenterology, endocrinology, dietetics, and psychology (Wills et al.) established consensus definitions. The consensus specifies: (i) percentage total weight loss (%TWL) as the preferred measurement approach (94.6% agreement); (ii) surgical non-response as \<10% TWL at 12 months (73.0%); (iii) recurrent weight gain as regain of more than 25% of lost weight from nadir (70.3%); and (iv) a change of up to 10% in percentage excess weight loss from nadir as a normal physiologic fluctuation not requiring intervention (83.8%). The consensus also endorsed 'suboptimal' as the preferred terminology for poor surgical response and reached unanimous agreement that anti-obesity medications may appropriately be prescribed by specialists in this population. These definitions supersede the heterogeneous thresholds used previously, including the >30% regain threshold of the 2024 IFSO Delphi, and are adopted throughout this protocol. Both IFSO and ASMBS now formally support pharmacotherapy as a therapeutic option for weight recurrence after MBS.

The 2024 IFSO international consensus on obesity management medications in the context of MBS reinforces this pathway: at 92% agreement, medications should generally be considered before revisional surgery for recurrent weight gain; at 100%, medication efficacy appears broadly preserved after MBS; and at 97%, no clear increase in adverse effects after MBS has been demonstrated. RESURGE supplies the randomized evidence behind the first of these statements.

Read the detailed description

Randomized evidence for GLP-1 receptor agonism after MBS has accumulated rapidly but in populations that do not correspond to the new consensus definition of recurrent weight gain. GRAVITAS demonstrated that liraglutide 1.8 mg improved glycemia in patients with persistent or recurrent type 2 diabetes after MBS. BARI-OPTIMISE randomized patients with suboptimal weight loss after RYGB or SG to liraglutide 3.0 mg versus placebo and reported 9.4% versus 1.1% weight loss at 24 weeks (treatment effect -8.8%; 95% CI -11.9 to -5.7). A randomized trial of liraglutide 3.0 mg specifically for weight recurrence after RYGB confirmed efficacy in that single-procedure setting. Most recently, the BARI-STEP trial randomized 70 adults at least 1 year after gastric bypass or SG with a suboptimal clinical response, defined as \<20% weight loss from the date of surgery, to semaglutide 2.4 mg weekly versus placebo for 68 weeks: mean weight change was -18.0% (SD 9.2) with semaglutide versus +0.4% (SD 7.0) with placebo, an adjusted treatment difference of -19.1% (95% CI -23.4 to -14.8), with a safety profile consistent with the known gastrointestinal tolerability of semaglutide and no new safety signals in the post-bariatric population. Meta-analyses support GLP-1 receptor agonists as effective adjuncts after MBS, and semaglutide 2.4 mg is superior to liraglutide 3.0 mg for weight reduction in head-to-head comparison.

No randomized trial has enrolled patients selected by the consensus definition of recurrent weight gain. BARI-STEP required \<20% TWL from surgery: 55.7% of its participants were regainers, but only regainers whose loss had already fallen back below 20% TWL. By construction it excludes the patient who achieved an excellent initial response (for example 30% TWL) and has since regained more than 25% of the weight lost while remaining above 20% TWL from surgery, and its own exploratory comparison of the two presentations was underpowered, with the investigators noting that their pathophysiology differs and calling for dedicated studies [8]. Its participants were also a mean of 83.9 months, seven years, past surgery, long after recurrence had hardened. In addition, one-anastomosis gastric bypass has appeared in a post-MBS randomized trial only as an unspecified fraction of BARI-STEP's 15-patient gastric-bypass subgroup; no trial has enrolled OAGB as a prespecified procedure stratum, and none has been conducted in a Middle East and North Africa population. RESURGE is designed to close these gaps: a randomized, double-blind, placebo-controlled trial of semaglutide 2.4 mg in patients who achieved an initial clinical response (nadir >=20% TWL) after primary SG, RYGB, or OAGB, stratified by procedure, who now meet the consensus recurrent weight gain definition, enrolled at the point of diagnosis rather than years later, with prespecified, rigorous measurement of treatment adherence and adverse effects.

Semaglutide 2.4 mg was selected over liraglutide on the basis of superior efficacy. demonstrated safety at 68 weeks in a post-bariatric randomized population, cardiovascular outcome benefit in adults with obesity, and once-weekly administration favoring adherence. A placebo-controlled, double-blind design with an identical lifestyle co-intervention in both arms is retained because lifestyle intensification alone can attenuate regain and because expectation effects on weight-related behavior are non-trivial; blinding is feasible using manufacturer-matched placebo pens through an investigator-initiated study scheme, the supply model used by BARI-STEP. The 68-week treatment duration (16-week escalation plus maintenance) matches the STEP program and BARI-STEP, permitting direct comparability of effect sizes.

The 2026 ADA and Obesity Association Standards strongly recommend continuing obesity pharmacotherapy through the maintenance phase. The week 68 to 80 off-treatment observation period therefore measures exactly the regain those Standards warn about, in a setting where continuation is often unaffordable, and hands the question of how to stop to the companion TAPER trial (Section 16).

03

Conditions studied

  • Morbid Obesity

Keywords

  • Semaglutide
  • Recurrent Weight Gain
  • Metabolic and Bariatric Surgery
  • RESURGE
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, or one-anastomosis gastric bypass performed at least 18 months before screening.
  • Documented initial clinical response: nadir weight loss of at least 20% TWL from preoperative weight.
  • Recurrent weight gain per Section 5.1: regain >25% of maximal weight lost, confirmed on two measurements at least 14 days apart.
  • Current >=30 kg/m2, or >=27 kg/m2 with at least one obesity-related complication (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, or symptomatic osteoarthritis).
  • Women of : willing to use highly effective during treatment and for 2 months after the last dose.
  • Able and willing to self-inject weekly, complete the injection diary, attend scheduled visits, and provide written .

Exclusion criteria

Exclusion Criteria:

  • Revisional or conversion bariatric surgery of any type, or revisional surgery planned during the trial period.
  • A surgically correctable anatomical cause of regain identified on the pre-enrolment work-up (Section 5.4), including gastro-gastric fistula or symptomatic pouch outlet abnormality, for which the patient elects surgical management.
  • Use of any GLP-1-based therapy, tirzepatide, or other anti-obesity medication within 6 months of screening.
  • Type 1 diabetes; type 2 diabetes treated with insulin.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  • History of acute or chronic pancreatitis.
  • Symptomatic gallstone disease.
  • Endoscopically active marginal or peptic ulcer, or anastomotic/sleeve stricture requiring intervention.
  • Pregnancy, breastfeeding, or intention to conceive during the trial. Obesity pharmacotherapy is stopped at least 2 months before any planned conception, per current semaglutide labeling and the 2026 Standards.
  • Estimated \<30 mL/min/1.73 m2; severe hepatic impairment.
  • . within the past 5 years (excluding treated non-melanoma skin cancer).
  • Current severe uncontrolled psychiatric illness, active suicidal ideation, suicide attempt within 5 years, or current or past diagnosed eating disorder.
  • Known or suspected alcohol or substance misuse.
  • Ongoing treatment with medications with effects on body weight (including systemic for more than 2 weeks).
  • Known to semaglutide or .
  • Participation in another interventional trial within 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Active comparator
    GLP 1

    Once-weekly subcutaneous semaglutide, escalated over 16 weeks (0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg) to 2.4 mg or maximum tolerated dose (minimum 1.0 mg), for 68 weeks, as an adjunct to structured lifestyle intervention (500 kcal/day deficit, \>=150 min/week moderate activity, protein \>=60 g/day)

    Drug: Semaglutide weekly injection

  • Placebo comparator
    Placebo

    Matched placebo pen, identical escalation schedule, with the same lifestyle intervention

    Drug: Placabo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide is supplied in pre-filled pens and administered subcutaneously once weekly, on the same weekday, at any time of day. Dose escalation: 0.25 mg (weeks 0-3), 0.5 mg (weeks 4-7), 1.0 mg (weeks 8-11), 1.7 mg (weeks 12-15), 2.4 mg from week 16 to week 68. Participants with unacceptable gastrointestinal symptoms may extend an escalation step by 4 weeks or down-titrate one step; the maintenance dose must be at least 1.0 mg for the participant to remain on treatment, mirroring the tolerance management applied in BARI-STEP.

  • DrugPlacabo

    Placebo pens are identical in appearance, volume, and escalation schedule.

06

What researchers measure

Primary outcomes

  1. Mean percentage change in body weight from randomization

    Measured in Kilograms

    Time frame: week 0 to week 68

Secondary outcomes

  1. absolute weight change

    Measured in kilograms

    Time frame: Baseline till week 68

  2. BMI change

    Equation: BMI = weight (In kilograms) / \[height (In meters)\]\^2

    Time frame: Baseline till week 68

  3. waist circumference change

    Waist circumference is a direct measurement of belly fat that helps assess your risk for chronic health issues like heart disease and type 2 diabetes. Health risk increases when waist size goes past certain thresholds: • Men: High risk starts above 102 cm (40 inches) according to standard guidelines, though some organizations flag risks starting at 94 cm (37 inches). • Women: High risk starts above 88 cm (35 inches), with tighter thresholds starting at 80 cm (31.5 inches) in some regional guidelines.

    Time frame: Baseline till week 68

  4. change in HbA1c

    An HbA1c level reflects your average blood sugar over the past two to three months, and any meaningful change typically takes at least 6 weeks to show because red blood cells live for about 3 months. Normal: Below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or higher

    Time frame: Baseline till week 68

  5. systolic and diastolic blood pressure

    Normal blood pressure is less than 120 mm Hg systolic and less than 80 mm Hg diastolic. Systolic (Top Number): Measures the pressure in your arteries when your heart beats and contracts. Diastolic (Bottom Number): Measures the pressure in your arteries when your heart rests between beats. * Normal: Less than 120 mm Hg systolic and less than 80 mm Hg diastolic. * Elevated: 120-129 mm Hg systolic and less than 80 mm Hg diastolic. * Stage 1 Hypertension (High Blood Pressure): 130-139 mm Hg systolic or 80-89 mm Hg diastolic. * Stage 2 Hypertension: 140 mm Hg or higher systolic, or 90 mm Hg or higher diastolic. * Hypertensive Crisis: Higher than 180 mm Hg systolic and/or higher than 120 mm Hg diastolic. This requires immediate emergency medical care

    Time frame: Baseline till week 68

  6. total cholesterol, LDL, HDL, and triglycerides

    Normal adult values for a lipid panel are measured in milligrams per deciliter (mg/dL): * Total Cholesterol: Below 200 mg/dL is desirable. (Borderline high is 200-239 mg/dL, and high is 240 mg/dL and above.) * LDL ("Bad") Cholesterol: Below 100 mg/dL is optimal. (130-159 mg/dL is borderline high, and 160-189 mg/dL or higher is high.) * HDL ("Good") Cholesterol: 60 mg/dL and higher is protective. Levels below 40 mg/dL for men or below 50 mg/dL for women are considered low. * Triglycerides: Below 150 mg/dL is normal. (Borderline high is 150-199 mg/dL, and high is 200-499 mg/dL.)

    Time frame: Baseline till week 68

  7. change in fat mass and lean soft tissue mass

    (bioelectrical impedance analysis, standardized hydration instructions), with fat-free mass loss reported as a proportion of total weight change and hand-grip strength measured at weeks 0, 32, and 68, so that mass is interpreted together with function per the ESPEN/EASO sarcopenic-obesity framework and current meta-analytic evidence.

    Time frame: weeks 0, 32, and 68

  8. change in IWQOL-Lite-CT total and domain scores

    The IWQOL-Lite-CT (Impact of Weight on Quality of Life-Lite Clinical Trials Version) score ranges from 0 to 100, where 100 represents the best possible quality of life and functioning (meaning zero weight-related impairment). * Total Score Range: 0-100 (higher = better quality of life) * Domain/Composite Scores: 0-100 * Raw scores are converted or transformed to a 0-100 scale for standard reporting.

    Time frame: Baseline till week 68

  9. change in GerdQ score

    A change in the GerdQ score reflects how gastroesophageal reflux disease (GERD) symptoms and their daily impact respond to treatment or evolve over time. * Range: The total score spans from 0 to 18. * Diagnosis Threshold: A score of 8 or higher indicates a high likelihood of GERD. * Components: It evaluates four positive predictors (heartburn, regurgitation, sleep disturbance, and over-the-counter medication use) and two negative predictors (epigastric pain and nausea) over the past 7 days. Decrease in Score: A lowering score (especially moving from ≥ 8 to \< 8) typically indicates successful treatment response, reduced symptom frequency, and lower disease impact. • Increase or No Change: A rising score or a score that remains persistently above 8 suggests ongoing treatment failure, unmanaged symptom triggers, or disease progression.

    Time frame: Baseline till week 68

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Apr 2029, 30 months later.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859150
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Responsible party
Mohamed Hany Ashour (Professor, Surgeon, General Committee of Teaching Hospitals and Institutes, Egypt) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Mohamed Hany Ashour, Professor, MD
Contact
mohamed.ashour@alexu.edu.eg
+201002600970

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion